{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-23-000033","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.162815+00:00","generated_at":"2026-06-15T04:22:48.506867+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Krystal Biotech presents long-term B-VEC data showing durable wound healing in DEB patients","bullets":["DDEB patient treated >2 years and RDEB patient >3 years with weekly topical B-VEC.","RDEB patient's wound burden decreased 80-90%, reverted from severe to intermediate generalized phenotype.","No significant adverse events attributed to B-VEC; treatment well tolerated.","RDEB patient showed systemic improvements: increased height, weight, and serum albumin levels.","Data presented at ISID meeting in Tokyo, May 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-23-000033","json":"https://secwatch.observer/filing/0001711279-23-000033.json","markdown":"https://secwatch.observer/filing/0001711279-23-000033.md","text":"https://secwatch.observer/filing/0001711279-23-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000033/0001711279-23-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000033/krys-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:22:48.506867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}